Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Telecon with Fresenius Kabi - 11/30/2007 - Voluven

Telecon with Fresenius Kabi

RE: BN070012

Meeting called by: Franklin. Stephenson/ RPM

Type of meeting: Telecon 919-881-9900

FDA Participants: Franklin Stephenson, Dr. Lawrence Landow

Baxter Participants: Mr. Coln


Conversation Record:

We contacted Mr. Coln and told him of the new Pediatric Research Equity Act (PREA) requirement that pediatric studies must be done in children. Dr. Landow explained that there were 3 categories in children: new born to 2 years, 2 years to 12 years and 12 years to 16 years.

Mr. Coln stated that Fresenius Kabi had provided a pediatric statement in Module 2 Vol 4, 3rd tab.

Dr. Landow noted that Fresenius Kabi had only done study in new born to 2 year old and needed to provide justification as to why a waiver should be granted for those age groups.

Mr. Coln told us that we would bring the issue to F. Kabi and would get back to us ASAP.

Franklin T. Stephenson
Regulatory Project Manager

Page Last Updated: 02/21/2017
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English